Children and family
Children are in good hands during clinical studies
Medication must be specifically tested on children in order to determine its effect on the children's organism. In Austria children with special needs which are caused by their primary diseases gain early access to new treatment options due to those studies. As those studies are particularly well monitored children usually are safer within a study than somewhere externally. Clinical studies for children make allowances for their needs in order to avoid an overload of stress.
Why carry out clinical studies on children?
A developing child's organism is different from an adult's organism, hence medication can cause different effects. So drugs must specifically be tested on children in order to ascertain correct dose, effects and side-effects in a systematic manner. If those details are not available, drugs can be ineffective or even be unsafe in children. The majority of drugs currently used for children has never been tested on children and are not approved for children either. New legislation, however, bind pharmaceutical manufacturers and physicians to test drugs on children and to get those approved for children.
OKIDS, the network for the research with children, makes its contribution to the aforementioned by interconnecting Austrian treatment centres and by supporting study teams on-site.
Why should my child participate in a study?
Drug safety testing not only gathers a wealth of information for future use in all affected children; it also brings immediate benefits to participating children. Children can gain early access to new treatment options due to those studies and they receive the best-possible concomitant therapy. In clinical studies children are particularly monitored in detail and in a systematic way, which is why treatment in a study is usually safer than a routine treatment. Sick children cannot be overburdened with excessive stress. Therefore children studies are specifically designed for them in order to make allowances for their special needs.
What is the alternative to study participation?
Your treating physician will inform you about treatment options and will explain to you which open questions remain regarding the current routine treatment. Your physician will also bring to light benefits and risks for your potentially participating child in comparison with the routine treatment. Study participation is voluntary and the decision to take part rests on the legal guardian(s) and the affected children, should they be old enough. Regardless what treatment you are going for, your child will always receive the best treatment of our knowledge and belief.
What is OKIDS?
OKIDS is a network for the research with children; experienced children's hospitals have teamed up in order to carry out drug safety testing on children in conjunction with each other. The advantage of this network is, that paediatricians pool their experiences whereby on the one hand best-possible routine treatment for children in close collaboration between the centres is achievable and, on the other hand new treatment options can be evaluated in co-ordination with the centres and international networks. OKIDS has established an expert forum consisting of Austrian paediatricians; it ensures the emphasis on drug safety testing in order to improve the currently most clamant treatment deficits for children. With the support of public funds OKIDS provides organisational structures allowing for safe, child-orientated and efficient handling of drug safety testing in the context of the treatment required.